stockrowRelay Therapeutics, Inc.
RLAY Healthcare Biotechnology
Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- 0.00%
- Free cash flow
- +2.13%
Quarter to June 2026, against a year earlier
Follow RLAY
Alert me
Relay Therapeutics, Inc. (RLAY) Operating cash flow
Relay Therapeutics, Inc.'s operating cash flow for fiscal 2025 was −$235.5M, compared with −$249.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$212.2M. Over the past ten years it has ranged from −$300.3M (fiscal 2023) to −$44.1M (fiscal 2018); the current reading is higher than 38% of that period. Relay Therapeutics, Inc. ranks 550th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$235.5M | — |
| FY2024 | −$249.1M | — |
| FY2023 | −$300.3M | — |
| FY2022 | −$229.5M | — |
| FY2021 | −$74.4M | — |
| FY2020 | −$102.5M | — |
| FY2019 | −$66.1M | — |
| FY2018 | −$44.1M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$54.1M | — |
| Mar 2026 | −$51.1M | — |
| Dec 2025 | −$44.9M | — |
| Sep 2025 | −$62.1M | — |
| 25 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $97.5M |
| ABCL AbCellera Biologics Inc. compare | −$94.9M |
| PBLS Parabilis Medicines, Inc. compare | −$118.1M |
| TNGX Tango Therapeutics, Inc. compare | −$143.9M |
| EWTX Edgewise Therapeutics, Inc. compare | −$158.4M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$190.0M |
| IRON Disc Medicine, Inc. compare | −$197.5M |
| RLAY Relay Therapeutics, Inc. | −$212.2M |
| XENE Xenon Pharmaceuticals Inc. compare | −$337.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on RLAY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement